Form 4: UTHR COO Benkowitz Exercises, Sells Shares

United Therapeutics Corp's President and COO, Michael Benkowitz, exercised stock options and sold the resulting shares totaling 22,500 under a pre-arranged 10b5-1 trading plan.

Summary

• Michael Benkowitz, President and COO of United Therapeutics Corp (UTHR), executed transactions involving the exercise of stock options and the subsequent sale of common stock on December 29, 2025.
• He exercised options for 14,625 shares at a price of $117.76 per share and immediately sold these shares at $502.7871 per share. These shares were held in a trust where Benkowitz and his spouse are co-trustees.
• Additionally, Benkowitz exercised options for 7,875 shares at $146.03 per share and sold these shares at $502.7871 per share. These shares were held in a trust for which he has sole investment and voting power.
• All reported transactions were conducted pursuant to a Rule 10b5-1 trading plan that was established on June 3, 2025.
• Following these transactions, Benkowitz directly holds 2,648 shares of common stock.
• He also indirectly holds 111,750 derivative securities (stock options) via one trust and 60,190 derivative securities (stock options) via another trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While an executive sale can sometimes be viewed negatively, these transactions were pre-planned under a 10b5-1 plan, indicating a structured approach rather than a reaction to new negative information. The executive realized significant gains, which is positive for the individual.

Positives

• The executive realized significant gains by exercising options at lower strike prices ($117.76 and $146.03) and selling the resulting shares at a higher market price ($502.7871).
• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which indicates a structured approach to managing equity holdings and reduces concerns about opportunistic insider trading.

Negatives

• The sale of 22,500 shares by a high-ranking executive, even under a 10b5-1 plan, could be perceived by some investors as a minor negative signal.

Future Outlook

NA

Industry Context

This filing is a routine insider transaction report and does not provide information relevant to broader industry trends or competitors.

Related Party Transactions

• The transactions involved trusts where the reporting person is a beneficiary and co-trustee (with spouse) or has sole investment and voting power (for family members' benefit), which are considered related party dealings in the context of beneficial ownership reporting.

Stakeholder Impact

• Shareholders: May view the sale as a neutral event due to the 10b5-1 plan, or potentially a minor negative signal if not fully understanding the context.

Key Dates

Recommendation

This Form 4 filing reports routine insider transactions executed under a pre-arranged 10b5-1 plan. While the sale of shares by an executive might typically raise questions, the existence of a 10b5-1 plan mitigates concerns about opportunistic selling based on undisclosed material information. The transactions reflect the executive's personal financial planning rather than a change in the company's fundamental outlook. Therefore, this filing alone does not provide sufficient new information to warrant a change from a 'hold' recommendation, assuming the company's fundamentals remain consistent with prior assessments.

Keywords

United Therapeutics, UTHR, Form 4, Insider Trading, Stock Options, Rule 10b5-1, Executive Compensation, Share Sale, Michael Benkowitz